The Development of BTK Inhibitors: A Five-Year Update - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34885993/
Bruton's tyrosine kinase (BTK) represented, in the past ten years, an important target for the development of new therapeutic agents that could be useful for cancer and autoimmune disorders. To...
Conclusion/Relevance: This review is focused on compounds that have appeared in the literature from 2017 that are able to block BTK in an irreversible or reversible manner; also, new promising tunable irreversible inhibitors, as well as PROTAC molecules, have been reported. This summary could improve the knowledge of the chemical diversity of...
Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors
Source : https://www.frontiersin.org/articles/10.3389/fimmu.2021.804735/full
In 1993 Bruton's tyrosine kinase (BTK; initially named ATK and BPK) was identified by two independent research groups. The corresponding gene, BTK, is mutated in X-linked agammaglobulinemia suggesting that inhibitors...
Conclusion/Relevance: While BTK is a central signal transducer for B lymphocyte development in both man and mouse, and is well-known to most immunologists, the dramatic events in the treatment of leukemia and lymphoma have mainly appeared in medical, hematological and oncological journals. For this reason, the editors believed that it would be...
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34838186/
Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after...
Conclusion/Relevance: Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Source : https://www.sciencedirect.com/science/article/abs/pii/S0223523421008588?via=ihub
BTK is a promising target for the treatment of hematologic malignancies. * Mechanisms of ibrutinib adverse effects and primary/acquired resistance. * The development of BTK inhibitors in overcoming the clinical...
Conclusion/Relevance: In this review, we summarize clinical developments of the first-, second- and third-generation BTK inhibitors, as well as recent advances in BTK-PROTACs and ibrutinib-based combination therapies.
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34858810/
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic...
Relevance: Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies.